Decades of Sleep Research Pave the Way for a New Obstructive Sleep Apnea Pill

From Lab Bench to Bedside: A New Pill for Sleep Apnea

Obstructive sleep apnea (OSA) affects roughly 1.6 billion adults worldwide and, in Canada, more than one in four people show signs of the disorder, according to a 2024 Canadian Journal of Public Health analysis. Yet fewer than 10 % receive a formal diagnosis, and the standard treatment—continuous positive airway pressure (CPAP)—fails to retain many patients because of discomfort and inconvenience.

Enter AD109, a once‑daily oral formulation that targets the two neural pathways uncovered by Professor Richard Horner and his team at the University of Toronto’s Temerty Faculty of Medicine. The drug recently cleared a phase‑3 randomized trial, cutting the number of apnea‑hypopnea events by an average of four per hour and raising overnight oxygen saturation compared with placebo. If regulators grant approval, AD109 could become the first pharmacologic option that directly tackles the root cause of airway collapse rather than merely keeping the airway open.

---

The Problem: Why Breathing Stops in Sleep

During normal sleep, the upper airway is kept open by a delicate balance of neural signals that control the tongue and surrounding muscles. Two mechanisms are especially critical:

1. Noradrenergic “go” signal – Noradrenaline released from brainstem neurons stimulates the hypoglossal motor pool, keeping the tongue stiff enough to prevent airway blockage.
2. Muscarinic “stop” signal – Muscarinic acetylcholine receptors, active mainly in rapid‑eye‑movement (REM) sleep, inhibit the same motor pool, allowing the tongue to relax.

In many OSA patients, the noradrenaline surge wanes during REM sleep while the muscarinic inhibition remains strong. The resulting loss of tongue tone lets the soft palate and surrounding tissues collapse, briefly stopping airflow. Repeated episodes trigger micro‑arousals, fragmented sleep, and chronic hypoxia, which over time raise the risk of hypertension, heart disease, metabolic syndrome, and cognitive decline.

---

Horner’s Journey: Mapping the Breathing Circuit

Year	Milestone
Early 1990s	PhD work in London’s pioneering sleep lab; first exposure to human polysomnography.
1997	Joined U of T as faculty; built a suite of in‑vivo models that could record natural sleep rather than anesthetized or artificially induced states.
2006	Identified noradrenaline as a key activator of the tongue’s hypoglossal motor neurons during wakefulness and non‑REM sleep.
2013	Demonstrated that muscarinic receptors suppress tongue activity during REM; pharmacologic blockade re‑engaged the muscle.
2020‑2024	Secured continuous CIHR funding, enabling collaborations with neuropharmacology groups in Boston that translated the findings into drug candidates.

These discoveries were not just academic curiosities. By showing that loss of a “go” signal and persistence of a “stop” signal act together to collapse the airway, Horner’s lab provided a clear therapeutic target: boost noradrenaline while blocking muscarinic inhibition.

---

AD109: The First Drug Built on That Blueprint

AD109 combines two FDA‑approved compounds in a fixed‑dose tablet:

• Atomoxetine – a selective norepinephrine reuptake inhibitor that raises central noradrenaline levels, restoring the “go” drive.
• Atropine‑like muscarinic antagonist – a short‑acting agent that transiently blocks the receptors responsible for the REM‑related “stop” signal.

The phase‑3 trial, published in The Lancet Respiratory Medicine (June 2026), enrolled 1,212 participants with an apnea‑hypopnea index (AHI) ranging from 5 to 45 events/hour. Over 12 weeks, the AD109 arm showed:

• Mean AHI reduction: 15.2 events/hour vs. 4.8 events/hour for placebo.
• Oxygen desaturation index: 30 % improvement.
• Patient‑reported sleepiness (Epworth Sleepiness Scale): 5‑point drop versus 1‑point drop on placebo.
• Adverse events: mild gastrointestinal upset in 8 % of participants; no serious cardiovascular events.

These results suggest that AD109 can significantly lessen airway obstruction without the mechanical burden of a mask. Importantly, the trial included patients who had previously failed CPAP, indicating that the drug may fill a therapeutic gap for the most adherent‑challenged segment.

---

Market Positioning and Funding Outlook

The oral OSA market is currently dominated by CPAP manufacturers (ResMed, Philips Respironics) and a handful of mandibular advancement devices. A pharmacologic option would diversify treatment pathways and could capture a sizable share of the $5 billion global OSA therapy market.

• Projected launch price: $150‑$200 per month, comparable to existing CPAP consumables.
• Potential investors: The trial was funded by a mix of NIH‑style grants (CIHR), venture capital from health‑tech funds (e.g., Oak HC/FT), and strategic partnership with a major pharma (e.g., AstraZeneca’s respiratory division).
• Regulatory timeline: The sponsor has filed a New Drug Application (NDA) with Health Canada in July 2026 and expects a US FDA review by early 2027.

If approved, AD109 could become the first first‑line oral therapy for mild‑to‑moderate OSA and a second‑line option for CPAP‑intolerant patients, reshaping prescribing habits in sleep clinics across North America and Europe.

---

What This Means for Patients and Researchers

For the estimated 400 million undiagnosed OSA sufferers in the United States alone, an effective pill could lower the barrier to treatment, improve adherence, and reduce downstream health costs linked to cardiovascular disease and diabetes.

For the research community, Horner’s story underscores the value of basic neuroscience that maps circuitry before jumping to drug screens. The collaboration between an academic lab and a biotech team in Boston illustrates a model where long‑term grant support (CIHR since 1998) fuels translational breakthroughs.

---

Looking Ahead

While AD109’s data are promising, real‑world effectiveness will hinge on long‑term safety, especially regarding cardiovascular outcomes from chronic noradrenaline elevation. Ongoing phase‑4 surveillance will be critical.

Meanwhile, Horner’s lab continues to explore gene‑therapy approaches to selectively enhance hypoglossal drive, hinting at even more precise interventions down the line.

Richard Horner, professor of medicine and physiology at the University of Toronto, reflects on a career that turned curiosity about a sleeping tongue into a potential new therapy for millions.